
The FY2027 appropriations process gives Congress an immediate opportunity to protect medical cannabis patients from discrimination while addressing the gaps left by the Attorney General's order. Through funding directives, legislative provisions, and committee report language, Congress can require federal agencies to protect patients, update outdated policies, and establish the safeguards necessary for safe access and healthcare integration. These actions cannot replace comprehensive medical cannabis legislation, but they can help ensure that patients are not left behind while Congress develops a national framework.
For ASA's complete appropriations agenda, detailed requests across all seven subcommittees, and the latest congressional developments, visit our FY2027 Medical Cannabis Appropriations Hub. The hub will be updated as Congress considers FY2027 funding legislation and patient advocacy opportunities.
DOWNLOAD PROPOSED CJS APPROPS LANGUAGE | TAKE ACTION
ADDRESSING PATIENT NEEDS THROUGH COMMERCE, JUSTICE, SCIENCE, & RELATED AGENCIES APPROPRIATIONS
The Commerce, Justice, Science, and Related Agencies (CJS) Subcommittee has a unique responsibility because Congress has relied on its appropriations bill to protect state medical cannabis programs for more than a decade, and the Department of Justice (DOJ) and Drug Enforcement Administration (DEA) are now responsible for implementing the first federal registration framework for qualifying medical cannabis activities. As federal policy moves from noninterference to active oversight, registration decisions will affect which state-licensed operations can participate in federally authorized medical cannabis supply chains and whether patients will continue to have reliable access to their medicine.
Congress must retain the Medical Cannabis CJS Amendment, reject new anti-rescheduling or punitive provisions, ensure fair and transparent DEA registration decisions, and direct DOJ to clarify patient rights under federal civil-rights laws. These actions will help ensure that federal oversight strengthens rather than disrupts state medical cannabis programs and the patients they serve.
ASA'S FY2027 APPROPRIATIONS REQUEST |
Americans for Safe Access requests that Congress preserve the longstanding Medical Cannabis CJS Amendment and ensure that anti-rescheduling restrictions and additional punitive provisions included in the House proposal remain excluded from the final FY2027 appropriations legislation. Congress should also direct DOJ to issue comprehensive civil-rights guidance addressing discrimination against state-authorized medical cannabis patients in housing, employment, healthcare, federally funded programs, and other settings, including protections concerning workplace drug testing and reasonable accommodation.
ASA further requests that Congress provide DOJ and DEA with the authority and direction necessary to implement federal medical cannabis registration without unnecessarily interrupting patient access. This includes reopening expedited registration opportunities, establishing transparent application and compliance standards, working with states and territories to resolve licensing and regulatory barriers, requiring regional patient-access assessments and congressional reporting, and preventing categorical registration denials based solely on prior cannabis-related convictions without individualized consideration of applicable public-health, safety, and diversion risks.
A. THE MEDICAL CANNABIS CJS AMENDMENT |
Since 2014, the Medical Marijuana CJS Amendment has protected state medical cannabis programs, patients, and healthcare providers from federal prosecution, arrest, asset forfeiture, and harassment. The provision has received bipartisan support for over a decade and serves as a critical safeguard as Congress works toward comprehensive medical cannabis legislation. This year, the House Appropriations Committee passed amendments that would block efforts to reschedule cannabis and modified the Medical Cannabis Amendment to open the door for federal interference in state medical cannabis programs again (with double penalties).
SEC. 531. (a) None of the funds made available under this Act to the Department of Justice may be used, with respect to any of the States of Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming, or with respect to the District of Columbia, the Commonwealth of the Northern Mariana Islands, the United States Virgin Islands, Guam, or Puerto Rico, to prevent any of them from implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana.
1. REMOVE SEC. 531(b):
Purpose: This new language undermines the Congressional intent behind the medical cannabis protections upheld for over a decade. Regulation of dispensary locations is the responsibility of individual states. Adding federal penalties risks destabilizing established, well-regulated programs and unfairly jeopardizes patient access.

SEC. 531(b): “Funds made available under this Act to the Department of Justice may be used to enforce violations of 21 U.S.C. 860.”
“21 U.S.C. 860”: Any person who is distributing, possessing with intent to distribute, or manufacturing a controlled substance in or on, or within one thousand feet of, a public or private elementary, vocational, or secondary school or a public or private college, junior college, or university, or a playground, or housing facility owned by a public housing authority, or within 100 feet of a public or private youth center, public swimming pool, or video arcade facility, is subject to: (1) twice the maximum punishment and (2) at least twice any term of supervised release for a first offense.
2. REMOVE SEC. 591:
Purpose: This section threatens to derail the federal cannabis rescheduling process, which has been underway since 2022. This effort has involved extensive scientific review and public engagement and is currently under administrative review. Congress maintains oversight authority, but interrupting a robust, science-based process midstream undermines both evidence-based policymaking and public trust.
SEC. 591. “None of the funds appropriated or otherwise made available by this Act may be used to reschedule marijuana (as such term is defined in section 102 of the Controlled Substances Act (21 U.S.C. 802)) or to remove marijuana from the schedules established under section 202 of the Controlled Substances Act (21 U.S.C. 812).”
B.FEDERAL MEDICAL CANNABIS PATIENT CIVIL RIGHTS & WORKPLACE PROTECTIONS UNDER AG ORDER NO. 6754-2026 |
Direct the Department of Justice (DOJ), through its Civil Rights Division, to issue guidance clarifying the application of the Americans with Disabilities Act (ADA), the Fair Housing Act, and Sections 501 and 504 of the Rehabilitation Act to individuals participating in state-authorized medical cannabis programs following Attorney General Order No. 6754-2026. The guidance should address discrimination in housing, employment, healthcare, federally funded programs, public accommodations, benefits, services, and reasonable-accommodation requests.
As part of this effort, DOJ should coordinate with the Office of Personnel Management (OPM), the Department of Health and Human Services (HHS), and the Substance Abuse and Mental Health Services Administration (SAMHSA) to evaluate federal workplace drug-testing policies, including pre-employment and random cannabis testing. The review should distinguish cannabis detection from evidence of current impairment, address individualized assessments and legitimate job-related safety requirements, protect sensitive medical information, and clarify how existing disability and employment laws apply to qualifying medical cannabis patients.
Patients continue to face discrimination because federal and institutional policies often rely on outdated assumptions about cannabis treatment and do not adequately distinguish participation in a medical cannabis program from impairment, misconduct, or documented safety concerns. Attorney General Order No. 6754-2026 changes the federal classification of qualifying medical cannabis products but does not independently resolve the application of every federal civil-rights statute or eliminate existing drug-free workplace requirements. DOJ guidance and coordinated legal review can clarify existing protections, identify policies that agencies can revise, and recommend legislative changes needed to prevent discrimination while preserving legitimate safety requirements.
PROPOSED BILL LANGUAGE
SEC. __. MEDICAL CANNABIS PATIENT CIVIL RIGHTS AND WORKPLACE PROTECTIONS.
(a) Federal Civil Rights Guidance. Not later than 30 days after the date of enactment of this Act, the Attorney General, acting through the Assistant Attorney General for the Civil Rights Division, shall issue public guidance regarding the application of the Americans with Disabilities Act, the Fair Housing Act, and sections 501 and 504 of the Rehabilitation Act to individuals participating in state-authorized medical cannabis programs following Attorney General Order No. 6754-2026.
Such guidance shall address housing, employment, healthcare, federally funded programs, public accommodations, benefits, services, and requests for reasonable accommodation. The guidance shall clarify the application of existing federal nondiscrimination requirements, standards for individualized assessment, actual impairment, documented health or safety risks, legitimate program requirements, and applicable statutory limitations, including restrictions relating to illegal drug use.
(b) Federal Workplace Civil Rights and Drug-Testing Review. Not later than 180 days after the date of enactment of this Act, the Attorney General, acting through the Civil Rights Division and in coordination with the Director of the Office of Personnel Management, the Secretary of Health and Human Services, and the Assistant Secretary for Mental Health and Substance Use, shall conduct an interagency review of federal workplace policies affecting state-authorized medical cannabis patients.
The review shall evaluate pre-employment and random cannabis testing; medical review officer procedures; the interpretation of cannabis-positive test results; individualized assessments of impairment, performance, misconduct, and job-related safety risks; protections for confidential medical information; and the application of the Americans with Disabilities Act, the Rehabilitation Act, and applicable federal drug-free workplace requirements.
The review shall specifically assess whether existing policies appropriately distinguish evidence of cannabis exposure from contemporaneous impairment and whether employment decisions based on cannabis-positive test results are consistent with applicable federal law, legitimate safety requirements, and the responsibilities of employees in safety-sensitive positions.
(c) Congressional Recommendations. Not later than 180 days after enactment, the Attorney General shall submit to the Committees on Appropriations a report identifying federal civil-rights guidance issued, policies requiring administrative or regulatory revision, unresolved statutory barriers, and recommendations for legislative action necessary to strengthen protections for qualifying medical cannabis patients.
The report shall include recommendations concerning federal employment and drug-testing policies, reasonable-accommodation procedures, medical information privacy, individualized assessments, and protections against discriminatory exclusions in federally regulated or funded programs. Recommendations shall distinguish actions available under existing federal authority from changes requiring congressional authorization.
PROPOSED COMMITTEE REPORT LANGUAGE
Medical Cannabis Patient Civil Rights and Federal Workplace Protections.
The Committee directs the Department of Justice, through its Civil Rights Division, to review the application of federal civil-rights protections to individuals participating in state-authorized medical cannabis programs following Attorney General Order No. 6754-2026. The review shall address the Americans with Disabilities Act, the Fair Housing Act, Sections 501 and 504 of the Rehabilitation Act, and other relevant federal requirements governing housing, employment, healthcare, federally funded programs, public accommodations, benefits, services, and reasonable accommodation.
The Committee further directs DOJ to coordinate with OPM, HHS, and SAMHSA in evaluating federal workplace drug-testing practices and employment policies affecting medical cannabis patients. The review shall examine pre-employment and random cannabis testing, interpretation of positive test results, medical review procedures, individualized assessment, actual impairment, job performance, documented safety risks, disability-related protections, and medical information confidentiality. Particular attention shall be given to distinguishing cannabis detection from contemporaneous impairment while preserving applicable federal drug-free workplace requirements and appropriate safeguards for safety-sensitive positions.
DOJ shall provide the Committees on Appropriations with its findings and recommendations within 180 days. The report shall identify outdated federal guidance, opportunities for administrative or regulatory changes, statutory barriers requiring congressional action, and recommended measures to ensure that federal policies appropriately protect qualifying medical cannabis patients from discrimination while maintaining legitimate public safety and program requirements.
C. ENSURING PATIENT ACCESS DURING FEDERAL MEDICAL CANNABIS REGISTRATION TRANSITION |
Attorney General Order No. 6754-2026 recognized that existing state medical cannabis regulatory programs could provide the foundation for federal registration, allowing DOJ and DEA to rely on state oversight while meeting federal statutory and international treaty obligations. The order was intended to incorporate existing state regulatory systems while minimizing disruption to patients. However, as DEA processes applications and begins issuing federal registrations, it is becoming clear that some states need more time to develop or revise regulatory frameworks that meet federal requirements and enable cannabis businesses to establish compliant medical-only supply chains.
The challenges are particularly acute in states and territories with combined medical and adult-use programs, where existing licensing structures and shared operations may prevent otherwise qualified medical cannabis businesses from meeting federal registration requirements. Some businesses that applied for federal registration face barriers arising from state laws or regulatory structures outside their control, while others did not apply because those same barriers appeared to prevent them from qualifying. Addressing these obstacles may require changes to state laws, regulations, licensing procedures, and business operations that could not be accomplished within the 60-day application period established by the Attorney General.
On October 30, 2026, DEA issued guidance stating that timely applicants are expected to establish compliant medical cannabis supply chains by November 29, 2026, adding urgency to resolving these issues. Patient access depends on functioning supply chains that include cultivation, manufacturing, testing, transportation, distribution, and dispensing, not simply the registration of individual dispensaries. Without additional time and federal coordination with states, registration barriers could leave patients in some geographic areas without an adequate federally authorized medical cannabis supply.
Attorney General Order No. 6754-2026 relies on the 1961 Single Convention on Narcotic Drugs to establish federal registration requirements for medical cannabis businesses. The Convention’s preamble recognizes that the medical use of narcotic drugs is indispensable for relieving pain and suffering and states that “adequate provision must be made to ensure the availability of narcotic drugs for such purposes.” The Controlled Substances Act (CSA), enacted in part to fulfill U.S. obligations under the Convention, similarly recognizes legitimate medical purposes alongside the need to prevent diversion. Congress found in 21 U.S.C. § 801(1) that many controlled substances have a “useful and legitimate medical purpose” and are necessary to public health. 21 U.S.C. § 823(a)(1) expressly pairs diversion controls with the objective of maintaining an “adequate and uninterrupted supply” for legitimate purposes, demonstrating that medical availability is an established consideration in federal drug control policy.
Congress must ensure that implementation of Attorney General Order No. 6754-2026 reflects the medical availability objectives recognized in both the CSA and the international treaty framework underlying the order. The FY2027 appropriations process provides an opportunity to address emerging registration barriers, support state regulatory transitions, and establish federal accountability for identifying and preventing gaps in patient access. Congressional action is especially important when compliance requires changes to state laws or licensing systems that individual applicants cannot undertake on their own.
Purpose: Congress should direct the DEA to identify potential medical cannabis access gaps as registration decisions are made and require the Attorney General to coordinate solutions to barriers outside individual applicants' control. DOJ should work directly with affected states and territories, along with relevant federal agencies, including the proposed Office of Medical Cannabis and Cannabinoid Control if established, to identify compliance solutions and provide reasonable time for necessary legislative, regulatory, licensing, or certification changes.
Congress should also provide additional, targeted registration authority to protect qualifying, timely applicants during approved state corrective-action periods and establish limited expedited registration opportunities once identified barriers are resolved. Those opportunities should include businesses that applied but could not obtain registration, businesses that did not apply because of state-level barriers, and otherwise qualified applicants affected by prior cannabis-related convictions. These provisions would address identified barriers without reopening federal registration or eliminating applicable diversion controls.
Congress should require DOJ and DEA to establish a patient-access continuity plan by December 26, 2026, identifying geographic areas at risk of lacking a complete federally authorized medical cannabis supply chain. The plan should identify state-level barriers contributing to these gaps, the federal and state corrective actions needed to resolve them, and the measures available to maintain patient access during the transition. A comprehensive report in January 2027 should evaluate registration decisions, implementation of corrective measures, remaining access barriers, and any additional statutory authority needed to ensure that federal registration requirements protect patients while fulfilling federal law and international treaty obligations.
PROPOSED BILL LANGUAGE
SEC. __. MEDICAL CANNABIS REGISTRATION, PATIENT ACCESS, AND IMPLEMENTATION ACCOUNTABILITY.
(a) DEA Registration Standards and Ongoing Identification of Patient Access Barriers.
Not later than 60 days after the date of enactment of this Act, the Administrator of the Drug Enforcement Administration shall publish objective criteria and procedural standards governing medical cannabis registration applications under Attorney General Order No. 6754-2026.
Such standards shall include written notice of identified deficiencies; meaningful opportunities to supplement or correct applications; procedures for reconsideration where authorized by law; and coordination with affected state and territorial regulatory authorities. The standards shall address combined medical and adult-use licensing systems, separate medical supply chains, inventory controls, product tracking, recordkeeping, security, licensing amendments, and certification requirements.
Where DEA identifies a state statute, regulation, license, certification procedure, or medical supply-chain requirement as inconsistent with the Controlled Substances Act, Attorney General Order No. 6754-2026, or an applicable international treaty obligation, the Administrator shall provide written identification of the specific requirement, the agency's legal reasoning, and the corrective measures necessary to achieve compliance.
The Administrator shall continuously evaluate information obtained through registration applications, communications with applicants, registration decisions, state licensing information, and other reasonably available sources to identify existing or reasonably anticipated gaps in lawful medical cannabis access. This evaluation shall include the availability and geographic distribution of federally registered cultivation, manufacturing, testing, transportation, distribution, and dispensing operations necessary to serve registered patients.
The Administrator shall also consult affected state and territorial regulatory authorities to identify otherwise qualified medical cannabis operations that did not submit applications during the original expedited registration period because state legislation, regulations, licensing classifications, certification procedures, or medical supply-chain requirements prevented their eligibility.
(b) Ongoing DEA Reporting to the Attorney General.
As federal medical cannabis registrations are issued, denied, proposed for denial, or delayed because of identified compliance concerns, the Administrator shall provide the Attorney General with ongoing assessments of their actual or anticipated consequences for lawful patient access.
Where DEA identifies a material existing or anticipated gap in medical cannabis supply, including a barrier that cannot be resolved through individual applicant action, the Administrator shall promptly notify the Attorney General and identify:
(1) The affected state, territory, or geographic region and available estimates of registered patients and therapeutic demand.
(2) The capacity and geographic distribution of federally registered or otherwise federally authorized medical cannabis operations serving the affected area.
(3) The registration decisions, application deficiencies, or legal and operational barriers contributing to the identified gap.
(4) The specific state or territorial legislation, regulations, licensing classifications, certification procedures, or medical supply-chain requirements preventing otherwise qualified applicants from obtaining federal registration.
(5) The corrective measures available through state legislative, regulatory, licensing, certification, or operational changes.
(6) The anticipated consequences for patient access while corrective measures are being developed or implemented.
(7) The federal coordination, interim operating arrangements, targeted registration flexibility, or additional authority necessary to prevent or resolve the identified interruption.
The Administrator shall update the Attorney General as material circumstances change and shall not defer identification or notification of patient-access problems pending completion of a scheduled congressional report.
(c) Attorney General Responsibility for Resolving State-Level Barriers and Maintaining Medical Access.
Upon receiving an assessment under subsection (b), the Attorney General shall evaluate the identified patient-access problem and direct DEA to develop and implement appropriate corrective measures. The Attorney General shall be responsible for coordinating the federal response and pursuing lawful solutions to prevent avoidable interruptions in medical cannabis access resulting from implementation of Attorney General Order No. 6754-2026.
The Attorney General shall work directly with affected state and territorial governments, including their medical cannabis regulatory authorities, and coordinate with relevant federal agencies. Such coordination shall include the Department of Health and Human Services and, if established, the Office of Medical Cannabis and Cannabinoid Control, to address patient needs, medical supply-chain capacity, continuity of care, product safety, and applicable federal requirements.
Where a state or territorial law, regulation, licensing structure, certification procedure, or medical supply-chain requirement prevents otherwise qualified applicants from obtaining federal registration, the Attorney General shall:
(1) Provide the affected jurisdiction with written identification of the specific federal statutory, regulatory, or treaty requirement that is not satisfied.
(2) Identify the legislative, regulatory, licensing, certification, or operational changes that would resolve the identified conflict.
(3) Establish a process through which the state or territory may submit a corrective-action plan.
(4) Provide technical assistance and coordinate with appropriate federal agencies to evaluate proposed corrective measures.
(5) Provide a reasonable implementation period that accounts for the time necessary for the jurisdiction to enact legislation, adopt regulations, amend licensing or certification procedures, or establish compliant medical supply-chain controls.
(6) Determine whether targeted interim operating arrangements or expedited federal registration procedures are necessary to prevent interruptions in lawful patient access while an approved corrective-action plan is implemented.
The Attorney General shall promptly review proposed corrective-action plans and provide written determinations identifying whether the proposed measures would resolve the cited deficiencies. Where a plan is approved, the Attorney General shall establish a reasonable implementation schedule and direct DEA to coordinate registration procedures with the affected jurisdiction.
In developing solutions, the Attorney General shall consider the legitimate medical purposes recognized in 21 U.S.C. § 801(1), the applicable registration requirements of the Controlled Substances Act, and United States obligations under the 1961 Single Convention on Narcotic Drugs, including its recognition of the need to maintain the availability of controlled substances for medical purposes while preventing diversion.
Where the Attorney General determines that no corrective measure is available under existing law or the authority provided by this section, the Attorney General shall identify the specific legal limitation and promptly notify the Committees on Appropriations of the additional authority required.
(d) Targeted Additional Registration Authority to Implement Corrective Measures.
To carry out subsection (c), and in addition to the registration authority otherwise available under the Controlled Substances Act, the Attorney General is authorized to establish targeted registration procedures and interim operating arrangements necessary to address identified patient-access interruptions arising from state-level barriers outside the control of otherwise qualified applicants.
(1) Interim Operating Authority for Timely Applicants Affected by State-Level Barriers.
Where an entity submitted an application during the original expedited registration period ending June 26, 2026, and the application remains pending, has been proposed for denial, or has been denied because of an identified state-level legal, regulatory, licensing, certification, or medical supply-chain barrier outside the applicant's control, the Attorney General may authorize continued qualifying medical cannabis activities during implementation of an approved state corrective-action plan.
For an applicant whose application remains pending, the Attorney General may preserve or extend qualifying interim operating authority under 21 C.F.R. § 1301.13(k)(7), subject to applicable requirements.
For an applicant whose timely application has been finally denied solely because of an identified state-level barrier, the Attorney General may issue a separate, time-limited interim authorization for specified qualifying medical cannabis activities. Such authorization may be issued notwithstanding the original expedited application deadline and, solely to the extent expressly authorized by this paragraph, the prior-registration requirement under 21 U.S.C. § 822(a).
Any such authorization shall require an affirmative written determination that the applicant holds valid state medical cannabis authorization, satisfies applicable applicant-specific requirements, and can conduct the specified activities under effective public-health, safety, security, record keeping, diversion-control, and applicable international treaty safeguards.
Interim authority shall be limited to the activities, facilities, and period necessary to implement the approved corrective-action plan and complete federal registration review. It shall not be available where denial rests on unresolved applicant-specific misconduct, diversion concerns, material falsification, or other disqualifying grounds unrelated to the identified state-level barrier.
(2) Expedited Registration for Applicants Affected by State-Level Barriers.
Where a state or United States territory has implemented legislative, regulatory, licensing, certification, or medical supply-chain changes under a corrective-action plan approved by the Attorney General, the Administrator shall establish a new 60-day expedited federal registration application period for otherwise qualified applicants whose eligibility was prevented by the identified state-level barrier.
The period shall begin upon the Attorney General's written determination that the approved corrective measures have been implemented and affected applicants may seek registration under the revised state or territorial program.
The expedited period shall be available to:
(A) Entities that submitted timely applications during the original expedited registration period but whose applications were denied, could not be approved, or remain pending because of the identified state-level barrier; and
(B) Otherwise qualified medical cannabis entities that did not submit applications during the original expedited period because state legislation, regulations, licensing classifications, certification procedures, or medical supply-chain requirements prevented their eligibility.
Applicants described in subparagraph (A) shall be permitted to amend, supplement, renew, or resubmit existing applications without unnecessary duplication of previously submitted documentation or fees. Applicants described in subparagraph (B) shall not be required to demonstrate that DEA previously denied an application but shall demonstrate that the identified state-level barrier prevented their eligibility during the original application period and that they now satisfy applicable state and federal requirements.
(3) Expedited Registration for Applicants Affected by Prior Cannabis-Related Convictions.
If Section __ of this Act concerning DEA registration and prior cannabis-related convictions is enacted, the Administrator shall establish a separate 60-day expedited application period for otherwise qualified state-licensed medical cannabis entities that did not apply during the original expedited registration period because prior cannabis-related convictions would have prevented or reasonably discouraged their eligibility under the registration standards then in effect.
Such applicants shall satisfy the revised eligibility standards established pursuant to Section __ and all other applicable federal registration requirements.
(4) Limitations and Oversight.
No additional expedited registration period shall be authorized under this section except following implementation of an approved state corrective-action plan under paragraph (2) or enactment of the prior-conviction protections described in paragraph (3).
The Attorney General shall not establish a general reopening of the original expedited registration period. Submission of an application under this subsection shall not, by itself, confer interim operating authority.
The Attorney General shall document the patient-access problem supporting each targeted action, the corrective measures undertaken, and their anticipated effect on lawful medical cannabis availability. Interim authorizations shall remain subject to applicable federal oversight, suspension, and termination procedures, including actions necessary to address documented threats to public health, safety, or diversion control.
(e) Medical Cannabis Patient Access and Supply Continuity Plan.
Not later than December 18, 2026, or five business days after the date of enactment of this Act, whichever is later, the Attorney General, acting through the Administrator of the Drug Enforcement Administration, shall submit to the Committees on Appropriations of the House of Representatives and the Senate a preliminary Medical Cannabis Patient Access and Supply Continuity Plan.
The plan shall identify states, territories, and geographic regions where the implementation of federal medical cannabis registration has created or is reasonably anticipated to create gaps in lawful medical cannabis availability. It shall be developed using information already available through registration applications, communications with applicants, registration determinations, state medical cannabis licensing records, and consultation with affected regulatory authorities.
The plan shall include:
(1) Regional Patient Access. The states, territories, and geographic areas where registered patients may lack adequate access to federally authorized medical cannabis products and services, together with available estimates of patient demand.
(2) Medical Supply-Chain Capacity. The number, location, and type of federal registrations issued or pending in affected jurisdictions, including whether federally registered dispensaries have access to sufficient authorized cultivation, manufacturing, testing, transportation, and distribution capacity.
(3) Identified State-Level Barriers. The specific state or territorial legislation, regulations, licensing classifications, certification procedures, or medical supply-chain requirements preventing otherwise qualified applicants from obtaining federal registration.
(4) Corrective-Action Plans. The steps DOJ and DEA are undertaking with affected states and territories to resolve identified barriers, including technical assistance, proposed or approved corrective-action plans, and reasonable implementation periods.
(5) Continuity of Medical Access. The lawful measures available to maintain medical cannabis supply while affected jurisdictions implement corrective measures, including targeted interim operating arrangements for qualifying timely applicants and expedited registration opportunities following approved state changes.
(6) Implementation Schedule. The anticipated schedule for federal and state corrective actions, responsible agencies and officials, and any additional statutory or regulatory authority required to address unresolved patient-access gaps.
The Attorney General shall provide a non-confidential public summary of the plan and promptly notify the Committees on Appropriations of material changes in identified access gaps or corrective actions.
(f) Comprehensive Congressional Report and Continuing Oversight.
Not later than January 31, 2027, or 30 days after enactment of this Act, whichever is later, the Attorney General shall submit a comprehensive public report evaluating implementation of federal medical cannabis registration under Attorney General Order No. 6754-2026.
The report shall address patient demand and medical supply; federal registration decisions; combined and dual-license programs; identified state and territorial conflicts; coordination and corrective-action opportunities; continuity of lawful patient access; and congressional action and accountability, as detailed in the accompanying committee report language.
Following the initial report, the Attorney General shall provide quarterly updates for one year describing registration decisions, changes in medical cannabis availability, state corrective-action plans, interim operating arrangements, limited expedited registration opportunities, and unresolved barriers affecting patient access. Reports shall protect patient privacy and confidential applicant information.
PROPOSED COMMITTEE REPORT LANGUAGE
Medical Cannabis Patient Access and Federal Registration Implementation.
The Committee recognizes that the Controlled Substances Act contemplates both legitimate medical purposes and effective controls against diversion. Section 801(1) of title 21, United States Code, recognizes the medical purposes of controlled substances and their importance to public health. Section 823(a)(1) expressly considers adequate and uninterrupted supply in the context of Schedule I and II manufacturing registrations; while that subsection does not directly apply to Schedule III, it reflects the broader statutory concern for legitimate medical availability. For Schedule III manufacturers and distributors, sections 823(e) and 823(f) require public-interest determinations that include effective diversion controls and consideration of applicable state law, while section 823(g) governs registration of practitioners, including dispensers.
The Committee further recognizes that the 1961 Single Convention on Narcotic Drugs identifies the need to ensure the availability of narcotic drugs for medical purposes alongside international requirements to prevent diversion. The Committee expects DOJ and DEA to administer qualifying medical cannabis registration in a manner that satisfies applicable federal statutory and treaty requirements while identifying lawful measures to prevent avoidable interruptions in patient access.
Patient Access and Supply Continuity Planning.
The Committee is concerned that the initial implementation of federal medical cannabis registration may create geographic gaps in lawful medical cannabis supply, particularly in states and territories where combined medical and adult-use licensing structures or other state-level requirements prevent otherwise qualified medical cannabis operations from obtaining federal registration.
DEA already possesses information through registration applications, communications with applicants, and registration determinations that can help identify these barriers and their anticipated consequences for patients. The Committee directs DEA to provide this information to the Attorney General on an ongoing basis and expects DOJ to work directly with affected state and territorial governments to develop solutions before gaps in medical supply result in interruptions in patient access.
The Committee requests a preliminary Medical Cannabis Patient Access and Supply Continuity Plan no later than December 18, 2026. The plan should identify existing and anticipated medical cannabis access deserts, gaps in federally registered cultivation, manufacturing, testing, transportation, distribution, and dispensing capacity, state-level barriers preventing registration, and the corrective measures DOJ and DEA are undertaking with affected jurisdictions.
The Committee expects the Attorney General to coordinate with relevant federal agencies, including the Department of Health and Human Services and the proposed Office of Medical Cannabis and Cannabinoid Control if established, to address patient needs, medical supply capacity, product safety, and continuity of care. Where state legislation, regulations, licensing classifications, certification procedures, or operational requirements prevent federal registration, DOJ should provide specific written guidance, establish corrective-action plans, and allow reasonable time for states and territories to implement necessary changes.
The Committee further expects DOJ to exercise the targeted additional authority provided in this Act to maintain appropriate medical operations for qualifying timely applicants affected by state-level barriers and establish limited expedited application periods following approved state corrective actions or enactment of the separate prior-conviction protections.
Comprehensive Registration and Patient Access Report.
The Committee directs the Attorney General, acting through the Drug Enforcement Administration, to provide a comprehensive report to the Committees on Appropriations not later than January 31, 2027, or 30 days after enactment, whichever is later. The report shall address the following:
(1) Patient Demand and Medical Supply. The number of registered patients, available estimates of therapeutic demand, and the capacity and geographic distribution of federally registered cultivation, manufacturing, testing, transportation, distribution, and dispensing operations, including locations where lawful medical supply may be inadequate or interrupted.
(2) Federal Registration Decisions. Aggregate numbers of initial, pending, approved, deficient, withdrawn, proposed-denial, and denied applications, including processing times, legal grounds for adverse determinations, differences by jurisdiction and license type, and consequences for patient access.
(3) Combined and Dual-License Programs. The legal and operational issues affecting state medical cannabis programs that permit combined medical and adult-use licenses, including inventory separation, tracking, security, recordkeeping, product classifications, and medical supply-chain requirements. DEA shall identify objective compliance criteria and whether license amendments or operational changes could resolve identified deficiencies.
(4) States and U.S. Territories with Identified Conflicts. For each jurisdiction in which DEA determines that a medical cannabis statute, regulation, license, or practice conflicts with the Controlled Substances Act, Attorney General Order No. 6754-2026, or applicable obligations under the 1961 Single Convention, the report shall identify the specific requirement, the agency's legal reasoning, and available corrective measures. DEA shall distinguish binding legal obligations from discretionary administrative implementation decisions.
(5) Coordination and Corrective-Action Opportunities. The procedures and designated federal contacts available for consultation with state and territorial regulators and affected applicants; technical assistance; opportunities to supplement registration applications; and reasonable procedures for revising licenses, regulations, inventory controls, certification requirements, or other compliance measures. The report shall identify the status of state corrective-action plans, opportunities for timely applicants affected by state-level barriers to maintain qualifying medical activities, and the implementation of limited expedited registration periods following approved state corrections.
(6) Continuity of Lawful Patient Access. The measures available to DOJ and DEA to reduce avoidable interruptions in medical supply while eligible applicants and jurisdictions pursue compliance, including the legal status of timely applicants whose registration decisions are affected by state-level barriers, the availability of lawful interim arrangements, and actions requiring additional statutory or regulatory authority. The report shall identify regional supply gaps, plans to address those gaps, and the impact of registration decisions on patients' ability to obtain medicine.
(7) Congressional Action and Accountability. Any additional statutory, funding, regulatory, or administrative actions necessary to establish a reliable medical cannabis supply while maintaining effective diversion controls. The report shall identify the results of DOJ's coordination with affected states and territories, unresolved compliance issues, and the effectiveness of corrective measures undertaken. Public reporting shall protect patient privacy and confidential applicant information.
The Committee further directs DOJ and DEA to evaluate the consequences of the original June 26, 2026, application deadline for state medical cannabis programs, including otherwise qualified entities that did not apply because of state-level barriers. The report shall assess the implementation of targeted registration authority, the adequacy of time provided for state corrective action, and the need for further congressional measures to prevent avoidable interruptions in patient access.
After submitting the initial report, the Attorney General shall provide quarterly updates for one year describing registration decisions, regional medical supply-chain capacity, the status of approved state corrective-action plans, the effectiveness of interim operating arrangements, and progress in resolving previously identified patient-access gaps.
D. DEA REGISTRATION & PRIOR CANNABIS-RELATED CONVICTIONS |
Direct DOJ and DEA to ensure that prior cannabis-related convictions are not treated as a categorical basis to deny DEA registration to state-licensed medical cannabis manufacturers, distributors, or dispensers.
Purpose: The DOJ order creates a federal registration process for state-licensed medical cannabis entities. Because the public-interest factors under 21 U.S.C. § 823 include prior controlled-substance convictions, DOJ and DEA must not use prior cannabis convictions as a blanket exclusion against people who helped operate state medical cannabis systems before federal law caught up.
PROPOSED BILL LANGUAGE:
None of the funds made available by this Act may be used by the Drug Enforcement Administration to deny registration to a state-licensed medical cannabis manufacturer, distributor, or dispenser solely on the basis of a prior cannabis- related conviction, absent an individualized determination that the applicant presents a current and documented risk to public health, safety, diversion control, or compliance with applicable international treaty obligations.
DOWNLOAD PROPOSED CJS APPROPS LANGUAGE | TAKE ACTION
THE PATH FORWARD |
The priorities outlined here are part of Americans for Safe Access' coordinated FY2027 appropriations agenda across seven congressional subcommittees. Together, these requests seek to protect patients, remove discriminatory barriers, strengthen federal accountability, and establish the policies necessary to integrate medical cannabis into American healthcare.
Congress can take meaningful action through the appropriations process while laying the groundwork for comprehensive medical cannabis legislation in the 120th Congress. Patients should not have to choose between the medicine they rely on and their healthcare, housing, livelihoods, or fundamental rights. Explore ASA's complete FY2027 Medical Cannabis Appropriations Agenda to learn how these requests work together and follow the latest congressional developments.
References & Sources
|
Share this page